These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 21540473)

  • 1. CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle.
    Dent P; Tang Y; Yacoub A; Dai Y; Fisher PB; Grant S
    Mol Interv; 2011 Apr; 11(2):133-40. PubMed ID: 21540473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells.
    Mitchell C; Park M; Eulitt P; Yang C; Yacoub A; Dent P
    Mol Pharmacol; 2010 Nov; 78(5):909-17. PubMed ID: 20696794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells.
    Booth L; Cruickshanks N; Ridder T; Dai Y; Grant S; Dent P
    Cancer Biol Ther; 2013 May; 14(5):458-65. PubMed ID: 23917378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.
    Chen Z; Xiao Z; Gu WZ; Xue J; Bui MH; Kovar P; Li G; Wang G; Tao ZF; Tong Y; Lin NH; Sham HL; Wang JY; Sowin TJ; Rosenberg SH; Zhang H
    Int J Cancer; 2006 Dec; 119(12):2784-94. PubMed ID: 17019715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents.
    Zenvirt S; Kravchenko-Balasha N; Levitzki A
    Oncogene; 2010 Nov; 29(46):6149-59. PubMed ID: 20729914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors.
    Tang Y; Hamed HA; Poklepovic A; Dai Y; Grant S; Dent P
    Mol Pharmacol; 2012 Aug; 82(2):322-32. PubMed ID: 22596349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest.
    Levesque AA; Fanous AA; Poh A; Eastman A
    Mol Cancer Ther; 2008 Feb; 7(2):252-62. PubMed ID: 18281511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy.
    Xiao Z; Xue J; Sowin TJ; Zhang H
    Mol Cancer Ther; 2006 Aug; 5(8):1935-43. PubMed ID: 16928813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer therapy with checkpoint inhibitors: what, where and when?
    Garrett MD; Collins I
    Trends Pharmacol Sci; 2011 May; 32(5):308-16. PubMed ID: 21458083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing CHK1 inhibitor lethality in glioblastoma.
    Tang Y; Dai Y; Grant S; Dent P
    Cancer Biol Ther; 2012 Apr; 13(6):379-88. PubMed ID: 22313687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics.
    Ma CX; Janetka JW; Piwnica-Worms H
    Trends Mol Med; 2011 Feb; 17(2):88-96. PubMed ID: 21087899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy.
    McNeely S; Beckmann R; Bence Lin AK
    Pharmacol Ther; 2014 Apr; 142(1):1-10. PubMed ID: 24140082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design.
    Thompson R; Eastman A
    Br J Clin Pharmacol; 2013 Sep; 76(3):358-69. PubMed ID: 23593991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition.
    Shibata H; Miuma S; Saldivar JC; Huebner K
    Cancer Sci; 2011 Oct; 102(10):1882-8. PubMed ID: 21707865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.
    Duan L; Perez RE; Hansen M; Gitelis S; Maki CG
    Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissecting the roles of checkpoint kinase 1/CDC2 and mitogen-activated protein kinase kinase 1/2/extracellular signal-regulated kinase 1/2 in relation to 7-hydroxystaurosporine-induced apoptosis in human multiple myeloma cells.
    Pei XY; Li W; Dai Y; Dent P; Grant S
    Mol Pharmacol; 2006 Dec; 70(6):1965-73. PubMed ID: 16940414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.
    Dai Y; Chen S; Shah R; Pei XY; Wang L; Almenara JA; Kramer LB; Dent P; Grant S
    Blood; 2011 Feb; 117(6):1947-57. PubMed ID: 21148814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
    Ma CX; Cai S; Li S; Ryan CE; Guo Z; Schaiff WT; Lin L; Hoog J; Goiffon RJ; Prat A; Aft RL; Ellis MJ; Piwnica-Worms H
    J Clin Invest; 2012 Apr; 122(4):1541-52. PubMed ID: 22446188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells.
    Dai Y; Chen S; Pei XY; Almenara JA; Kramer LB; Venditti CA; Dent P; Grant S
    Blood; 2008 Sep; 112(6):2439-49. PubMed ID: 18614762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ATR/CHK1 inhibitors and cancer therapy.
    Qiu Z; Oleinick NL; Zhang J
    Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.